GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903845 describes any process that stops, prevents, or reduces the cellular response to transforming growth factor beta (TGF-beta).
• TGF-beta signaling is a central regulator of cell proliferation, differentiation, migration, and extracellular matrix production, and its negative regulation is essential for tissue homeostasis [1, 7].
• Key negative regulators include SMAD7, SKI, SNO N, and phosphatases that target TGF-beta receptors or SMAD proteins [1, 7].
• Loss of negative regulation contributes to cancer, fibrosis, and developmental disorders, making this GO term highly relevant to disease research [1, 5].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of negative regulators in TGF-beta signaling [1, 7].
• EDITGENE provides end-to-end CRISPR services, including library screening and bioinformatics, to accelerate discovery in this pathway [1, 5].
Description
The Gene Ontology term GO:1903845, negative regulation of cellular response to transforming growth factor beta stimulus, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of a cell's response to TGF-beta. TGF-beta is a pleiotropic cytokine that controls diverse cellular programs, including proliferation, differentiation, apoptosis, and extracellular matrix remodeling [1, 7]. Because excessive or prolonged TGF-beta signaling drives pathological conditions such as cancer progression and fibrosis, negative regulation is critical for maintaining normal tissue homeostasis [1, 5].
negative regulation of cellular response to transforming growth factor beta stimulus At A Glance
| GO ID | GO:1903845 |
|---|---|
| GO term | negative regulation of cellular response to transforming growth factor beta stimulus |
| Ontology | biological_process |
| Synonym | inhibition of cellular response to TGF-beta stimulus; downregulation of cellular response to TGFbeta stimulus |
| Major function | Attenuation or termination of TGF-beta signaling to prevent excessive cellular responses |
| Related processes | SMAD-dependent and SMAD-independent TGF-beta signaling, receptor endocytosis, transcriptional repression |
| Disease relevance | Cancer, fibrosis, developmental disorders, and immune dysregulation |
| Research tools | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:1903845?
GO:1903845 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cellular response to transforming growth factor beta stimulus. It includes mechanisms such as receptor degradation, inhibitory SMAD activity, and transcriptional repression of TGF-beta target genes [1, 7].
Why Is negative regulation of cellular response to transforming growth factor beta stimulus Important in Cell Biology?
Negative regulation of TGF-beta signaling is essential for preventing uncontrolled cell growth, fibrosis, and immune dysfunction. Dysregulation of this process is implicated in triple-negative breast cancer, renal cell carcinoma, and cardiac fibrosis [1, 5, 7]. Understanding the molecular players and mechanisms provides opportunities for therapeutic intervention and biomarker discovery.
• Prevents excessive TGF-beta-induced growth inhibition or promotion depending on cell context.
• Controls epithelial-mesenchymal transition (EMT) and metastasis in cancer.
• Limits fibrosis in heart, kidney, and lung by reducing extracellular matrix deposition.
• Maintains immune homeostasis by regulating T cell differentiation and tolerance.
• Modulates stem cell self-renewal and differentiation.
• Influences hematopoiesis and leukemia progression [3, 4, 6].
• Affects renal cell carcinoma biology through IGFBP5 and related pathways.
• Regulates bone morphogenetic protein signaling cross-talk.
• Provides targets for CRISPR-based functional genomics [1, 5].
• Serves as a model for studying signaling brakes in development and disease.
What Happens During negative regulation of cellular response to transforming growth factor beta stimulus?
Receptor-level inhibition
In simple terms: Cells can reduce TGF-beta signaling by removing or blocking the receptors on the cell surface.
Negative regulation at the receptor level involves inhibitory SMAD7, which recruits E3 ubiquitin ligases to degrade TGF-beta receptors, and phosphatases that dephosphorylate activated receptors. This prevents downstream SMAD activation and dampens the cellular response.
SMAD-mediated negative feedback
In simple terms: Inside the cell, certain proteins act as brakes on the signaling cascade.
SMAD7 inhibits SMAD2/3 phosphorylation by competing with SMAD4 and promoting receptor degradation. Transcriptional corepressors such as SKI and SNO N bind to SMAD complexes and repress TGF-beta target genes, providing a negative feedback loop [1, 7].
SMAD-independent pathways
In simple terms: TGF-beta can also signal through non-SMAD routes, which are subject to separate negative regulation.
TGF-beta activates MAPK, PI3K/AKT, and Rho-like GTPase pathways. Negative regulators include phosphatases (e.g., PTEN) and inhibitory proteins that attenuate these branches, as shown in cardiac myofibroblasts where TGF-beta1 regulates Scleraxis via a SMAD-independent mechanism.
Transcriptional and epigenetic control
In simple terms: Cells can turn off genes that promote TGF-beta signaling or turn on inhibitory genes.
Epigenetic regulation, including DNA methylation and histone modifications, modulates the expression of TGF-beta pathway components. In triple-negative breast cancer, epigenetic changes in TGF-beta signaling genes affect the cellular response. Transcription factors such as those used for RPE reprogramming can restore mesenchymal cells by altering TGF-beta responsiveness.
Key Genes Involved in GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
The following genes and proteins are central to the negative regulation of TGF-beta signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD7 | Inhibitory SMAD; blocks receptor-mediated SMAD2/3 activation | Key negative regulator; target for cancer and fibrosis |
| SKI | Transcriptional corepressor of SMAD complexes | Oncogene and regulator of differentiation |
| SNO N | Corepressor that inhibits TGF-beta target genes | Involved in cancer and development |
| SMURF1 | E3 ubiquitin ligase targeting TGF-beta receptors | Regulates receptor turnover |
| SMURF2 | E3 ubiquitin ligase for receptor and SMAD degradation | Modulates signaling strength |
| STRAP | Inhibits SMAD2/3 phosphorylation | Negative regulator in cancer |
| PTEN | Phosphatase that antagonizes PI3K/AKT branch | Cross-talk with TGF-beta |
| IGFBP5 | Modulates TGF-beta signaling and cell growth | Target in renal cell carcinoma |
| SCX (Scleraxis) | TGF-beta1-regulated transcription factor in myofibroblasts | Cardiac fibrosis model |
| BMP6 | Cross-talk with TGF-beta superfamily | Regulated by hypoxia mimetics |
| SMAD2 | Receptor-regulated SMAD; subject to negative regulation | Central signaling node |
| SMAD3 | Receptor-regulated SMAD; subject to negative regulation | Central signaling node |
| SMAD4 | Common SMAD; partner for SMAD2/3 | Integrator of signaling |
| TGFBR1 | TGF-beta receptor type I; target of negative regulation | Receptor kinase |
| TGFBR2 | TGF-beta receptor type II; target of negative regulation | Receptor kinase |
| JUNB | Transcription factor that negatively regulates TGF-beta responses | Immediate early gene |
| KLF4 | Transcription factor that can inhibit TGF-beta signaling | Reprogramming factor |
How Is negative regulation of cellular response to transforming growth factor beta stimulus Regulated?
Negative regulation of TGF-beta signaling is itself tightly controlled. SMAD7 expression is induced by TGF-beta as a negative feedback loop, and its stability is regulated by ubiquitination and deubiquitination. Cross-talk with other pathways, such as BMP signaling, modulates the strength of inhibition. In hematopoiesis, negative regulators ensure balanced differentiation and proliferation [3, 4, 6].
negative regulation of cellular response to transforming growth factor beta stimulus and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD7 | Triple-negative breast cancer, fibrosis | Knockout and overexpression in cancer cell lines |
| IGFBP5 | Kidney renal papillary renal cell carcinoma | Knockdown and overexpression in renal cancer cells |
| SCX | Cardiac fibrosis | Knockout in primary cardiac myofibroblasts |
| BMP6 | Hypoxia-related signaling | Point mutation and knock-in in HepG2 cells |
| KLF4 | RPE reprogramming | Overexpression in mesenchymal RPE cells |
Cancer
Loss of negative regulation of TGF-beta signaling contributes to tumor progression. In triple-negative breast cancer, epigenetic silencing of negative regulators enhances TGF-beta responses, promoting EMT and metastasis. In renal cell carcinoma, IGFBP5, a probable target, modulates TGF-beta signaling and is associated with tumor biology.
Fibrosis
In cardiac myofibroblasts, TGF-beta1 regulates Scleraxis via a SMAD-independent mechanism, and impaired negative regulation leads to excessive extracellular matrix deposition and fibrosis. Similar mechanisms operate in kidney and lung fibrosis.
Developmental and hematological disorders
Negative regulators of TGF-beta signaling are essential for normal hematopoiesis; their dysregulation is linked to leukemia and bone marrow failure [3, 4, 6]. In retinal pigment epithelium, transcription factor-mediated reprogramming restores mesenchymal RPE by modulating TGF-beta responsiveness.
From negative regulation of cellular response to transforming growth factor beta stimulus-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SMAD7 enhance TGF-beta signaling? | SMAD7 knockout cell line |
| Does a point mutation in SMAD7 affect its inhibitory function? | Point mutation knock-in |
| Can overexpression of SKI block TGF-beta target genes? | SKI overexpression |
| How does IGFBP5 modulate TGF-beta response in renal cancer? | IGFBP5 knockout and overexpression |
| What is the role of SCX in cardiac fibrosis? | SCX knockout in myofibroblasts |
| Does BMP6 cross-talk with TGF-beta? | BMP6 knock-in and point mutation |
How to Study the negative regulation of cellular response to transforming growth factor beta stimulus Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify TGF-beta target genes after knockout |
| Proteomics | Protein interactions and modifications | Map SMAD7 interactome |
| Luciferase reporter | TGF-beta signaling activity | Quantify negative regulation |
| Immunofluorescence | SMAD nuclear translocation | Visualize signaling dynamics |
| CRISPR screen | Loss-of-function phenotypes | Discover novel regulators |
| Western blot | Protein levels and phosphorylation | Validate SMAD7 function |
| qPCR | mRNA levels of target genes | Confirm transcriptional changes |
Transcriptomic profiling
RNA-seq after CRISPR knockout or overexpression of negative regulators reveals global changes in TGF-beta target genes. This approach has been used to study epigenetic regulation in TNBC.
Proteomic analysis
Mass spectrometry-based proteomics identifies protein-protein interactions and post-translational modifications of SMAD7, SKI, and other negative regulators.
Imaging and reporter assays
Live-cell imaging of SMAD2/3 nuclear translocation and TGF-beta-responsive luciferase reporters quantifies signaling strength in real time.
Functional genomics screens
CRISPR library screens can identify novel negative regulators of TGF-beta signaling. Bioinformatics analysis prioritizes candidate genes for validation [1, 5].
How CRISPR Can Be Used to Study GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
Knockout
CRISPR knockout of negative regulators such as SMAD7, SKI, or SNO N leads to enhanced TGF-beta signaling, providing causal evidence for their inhibitory role.
Point Mutation
Introducing point mutations in catalytic or interaction domains of SMAD7 or SMURF2 can dissect domain-specific functions without altering protein levels.
Knock-in
Knock-in of tagged versions (e.g., HA-SMAD7) allows endogenous localization and interaction studies under physiological expression levels.
Overexpression
Overexpression of negative regulators like SKI or SNO N can suppress TGF-beta responses, useful for testing therapeutic potential [1, 7].
How EDITGENE Supports negative regulation of cellular response to transforming growth factor beta stimulus Research
Researchers studying negative regulation of cellular response to transforming growth factor beta stimulus-related genes often need to determine whether a candidate gene is causally involved in the pathway. EDITGENE provides CRISPR-based cell model services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cellular response to transforming growth factor beta stimulus research.
Frequently Asked Questions About negative regulation of cellular response to transforming growth factor beta stimulus
What is GO:1903845?
GO:1903845 is a Gene Ontology biological process term for any process that stops, prevents, or reduces the cellular response to transforming growth factor beta stimulus.
What genes are involved in negative regulation of TGF-beta signaling?
Key genes include SMAD7, SKI, SNO N, SMURF1, SMURF2, STRAP, and PTEN, among others [1, 7].
How does SMAD7 inhibit TGF-beta signaling?
SMAD7 binds to TGF-beta receptors and recruits E3 ubiquitin ligases to degrade them, preventing SMAD2/3 activation.
What diseases are linked to defective negative regulation of TGF-beta?
Cancer, fibrosis, and developmental disorders are associated with impaired negative regulation [1, 5, 7].
How can CRISPR be used to study this pathway?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of negative regulators.
What methods measure TGF-beta signaling activity?
Luciferase reporters, SMAD nuclear translocation imaging, RNA-seq, and proteomics are commonly used [1, 7].
Is IGFBP5 a negative regulator of TGF-beta?
IGFBP5 modulates TGF-beta signaling and is a probable target in renal cell carcinoma.
What is the role of SKI in TGF-beta signaling?
SKI is a transcriptional corepressor that inhibits SMAD-mediated gene expression.
Can negative regulation of TGF-beta be targeted therapeutically?
Yes, enhancing negative regulation is a strategy to treat fibrosis and cancer [1, 7].
What services does EDITGENE offer for this pathway?
EDITGENE provides knockout, point mutation, knock-in, overexpression, CRISPR library screening, and bioinformatics services [1, 5].
Conclusion
GO:1903845 represents a critical layer of control in TGF-beta signaling, with profound implications for cancer, fibrosis, and development. Understanding its mechanisms through CRISPR-based models and multi-omics approaches can reveal new therapeutic targets. EDITGENE offers comprehensive services to support such research.
References
- 1. Vishnubalaji R et al.. 2021. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling.. Sci Rep 11(1):15410 PMID: 34326372
- 2. Shih YH et al.. 2017. Restoration of Mesenchymal RPE by Transcription Factor-Mediated Reprogramming.. Invest Ophthalmol Vis Sci 58(1):430-441 PMID: 28118667
- 3. Sachs L. 1992. The molecular control of hematopoiesis: from clonal development in culture to therapy in the clinic.. Int J Cell Cloning 10(4):196-204 PMID: 1645028
- 4. Sachs L. 1996. The control of hematopoiesis and leukemia: from basic biology to the clinic.. Proc Natl Acad Sci U S A 93(10):4742-9 PMID: 8643473
- 5. Wang S et al.. 2019. Insulin-Like Growth Factor Binding Protein 5-A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma.. Biomed Res Int 2019:3210324 PMID: 31886201
- 6. Sachs L. 1993. The molecular control of hemopoiesis and leukemia.. C R Acad Sci III 316(9):871-91 PMID: 8076216
- 7. Zeglinski MR et al.. 2016. TGFβ1 regulates Scleraxis expression in primary cardiac myofibroblasts by a Smad-independent mechanism.. Am J Physiol Heart Circ Physiol 310(2):H239-49 PMID: 26566727
- 8. Noguchi T et al.. 2020. Regulatory expression of bone morphogenetic protein 6 by 2,2'-dipyridyl.. Biochim Biophys Acta Gen Subj 1864(8):129610 PMID: 32251709
